Corporate News
Novabridge Biosciences (ticker: NBP) closed the trading session on Thursday, 22 September 2026, down 3.86 % at 07:43 AM Central Europe time. The share price was reported at USD 1.37.
Key market data
| Item | Value |
|---|---|
| Shares outstanding | 116 million |
| Market capitalization | USD 165.3 million |
| 24‑hour trading volume | USD 803.5 thousand |
| 200‑day simple moving average | USD 2.27 |
| 52‑week high | USD 5.19 (1 June 2026) |
| 52‑week low | USD 1.26 (16 October 2026) |
| Month‑to‑month change | –13.84 % |
During the same 24‑hour period, the following peer stocks recorded the following movements:
- Duos (DUOT) – up 8.45 %, price USD 6.29, market cap USD 198 million, P/E 3.88.
- Z Squared (ZSQR) – down 2.44 %, price USD 3.60, market cap USD 195.6 million.
- Consumer Portfolio Services (CPSS) – flat 0 %, price USD 8.97, market cap USD 196.5 million, P/E 9.92.
- Stellus Capital Investment C (SCM) – down 1.17 %, price USD 6.75, market cap USD 194.5 million, P/E 6.63.
- Gopro (GPRO) – down 3.18 %, price USD 1.06, market cap USD 197.7 million.
Company profile
Novabridge Biosciences, operating under the brand name I‑Mab Biopharma, is a clinical‑stage biopharmaceutical company headquartered in Shanghai, China. The company focuses on the discovery, development, and commercialization of novel biologics targeting significant unmet medical needs, with a particular emphasis on cancers and autoimmune disorders. I‑Mab operates within the healthcare sector.
